A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease
NCT ID: NCT00087724
Last Updated: 2012-06-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
510 participants
INTERVENTIONAL
2004-07-31
2006-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease
NCT00945672
Efficacy and Safety of PRJ212 to Improve the Memory of Patients With Mild Severity Alzheimer's Disease
NCT02991235
MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)
NCT00362024
Study of LM11A-31-BHS in Mild-moderate AD Patients
NCT03069014
A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
NCT01677754
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FK962
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has a score =\< 4 on the Modified Hachinski Ischemia Scale at the screening visit
Exclusion Criteria
* Subject has a history of stroke
* Subject has been treated for schizophrenia or recurrent mood disorder within the previous three years
* Subject has a hematologic or solid malignancy diagnosed within five years prior to study entry
* Subject has medically unstable COPD or asthma
* Subject has end stage CHF (NYHA Class III or IV) or unstable angina
* Subject has evidence of significant renal insufficiency
* Subject has insulin-dependent diabetes mellitus or HbA1C\>8.5% at screening
50 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma US, Inc.
INDUSTRY
Astellas Pharma Inc
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Use Central Contact
Role: STUDY_DIRECTOR
Astellas Pharma US, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Investigational Site
Phoenix, Arizona, United States
Investigational Site
Phoenix, Arizona, United States
Sun City, Arizona, United States
Investigational Site
Tucson, Arizona, United States
Investigational Site
Little Rock, Arkansas, United States
Investigational Site
Little Rock, Arkansas, United States
Investigational Site
Fresno, California, United States
Investigational Site
Irvine, California, United States
Investigational Site
Orange, California, United States
Investigational Site
San Francisco, California, United States
Investigational Site
Sherman Oaks, California, United States
Investigational Site
Torrance, California, United States
Investigative Site
Denver, Colorado, United States
Investigational Site
Denver, Colorado, United States
Investigational Site
Darien, Connecticut, United States
Investigational Site
Hamden, Connecticut, United States
Hamden, Connecticut, United States
Investigational Site
Stamford, Connecticut, United States
Investigational Site
Fort Myers, Florida, United States
Investigational Site
Hialeah, Florida, United States
Investigational Site
Hollywood, Florida, United States
Investigational Site
Miami, Florida, United States
Investigational Site
North Miami, Florida, United States
Investigational Site
Ocala, Florida, United States
Investigational Site
Port Charlotte, Florida, United States
Investigational Site
Sarasota, Florida, United States
Investigational Site
Sebring, Florida, United States
Investigational Site
Tampa, Florida, United States
West Palm Beach, Florida, United States
Investigational Site
Snellville, Georgia, United States
Snellville, Georgia, United States
Investigational Site
Elk Grove, Illinois, United States
Investigational Site
Wichita, Kansas, United States
Investigational Site
New Orleans, Louisiana, United States
Baltimore, Maryland, United States
Investigational Site
Newton, Massachusetts, United States
Livonia, Michigan, United States
Hattiesburg, Mississippi, United States
Investigational Site
St Louis, Missouri, United States
Investigational Site
Las Vegas, Nevada, United States
Investigational Site
Long Branch, New Jersey, United States
Investigational Site
Paterson, New Jersey, United States
Investigational Site
Piscataway, New Jersey, United States
Investigational Site
Albuquerque, New Mexico, United States
Investigational Site
Albany, New York, United States
Investigational Site
Buffalo, New York, United States
Investigational Site
Lawrence, New York, United States
Investigational Site
New York, New York, United States
Investigational Site
White Plains, New York, United States
Charlotte, North Carolina, United States
Investigational Site
Centerville, Ohio, United States
Investigational Site
Columbus, Ohio, United States
Dayton, Ohio, United States
Investigational Site
Dayton, Ohio, United States
Investigational Site
Toledo, Ohio, United States
Investigational Site
Oklahoma City, Oklahoma, United States
Investigational Site
Tulsa, Oklahoma, United States
Investigational Site
Eugene, Oregon, United States
Investigational Site
Medford, Oregon, United States
Investigational Site
Bala-Cynwyd, Pennsylvania, United States
Investigational Site
Jenkintown, Pennsylvania, United States
Investigational Site
Pawtucket, Rhode Island, United States
Investigational Site
Johnson City, Tennessee, United States
Investigational Site
Nashville, Tennessee, United States
Investigational Site
Houston, Texas, United States
Investigational Site
San Antonio, Texas, United States
Investigational Site
Wichita Falls, Texas, United States
Investigational Site
Salt Lake City, Utah, United States
Investigational Site
Bennington, Vermont, United States
Burlington, Vermont, United States
Investigational Site
Norfolk, Virginia, United States
Investigational Site
Milwaukee, Wisconsin, United States
Investigational Site
Kelowna, British Columbia, Canada
Investigational Site
Penticton, British Columbia, Canada
Investigational Site
Victoria, British Columbia, Canada
Investigational Site
Sydney, Nova Scotia, Canada
Investigational Site
Barrie, Ontario, Canada
Investigational Site
Greater Sudbury, Ontario, Canada
Investigational Site
North York, Ontario, Canada
Investigational Site
North York, Ontario, Canada
Investigational Site
Ottawa, Ontario, Canada
Investigational Site
Toronto, Ontario, Canada
Investigational Site
Willowdale, Ontario, Canada
Investigational Site
Regina, Saskatchewan, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
03-0-189
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.